Skip to main content
SpringerLink
Log in

Drug Transporters

  • Chapter
  • First Online:
Handbook of Drug-Nutrient Interactions

Part of the book series: Nutrition and Health ((NH))

Objectives

• Illustrate the critical importance of uptake and efflux transporters to drug disposition and maintenance of normal physiologic homeostasis.

• Discuss major uptake and efflux transporters involved in the absorption, tissue distribution, and excretion of endobiotic and exobiotic compounds.

• Demonstrate the complexity of tissue-specific expression, overlap, and distribution of transporters are important to drug disposition.

• Highlight the importance of drug transporters to clinically observed drug–drug interactions, drug–nutrient interactions, and drug-mediated adverse effects.

• Underscore the notion that genetic heterogeneity in drug transporter genes contributes to the oft witnessed interindividual variability in drug disposition.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wilkinson G. Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 2001:3–29.

    Google Scholar 

  2. Ross EM, Kenakin TP. Pharmacodynamics: Mechanisms of Drug Action and the Relationship between Drug Concentration and Effect. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 2001:31–43.

    Google Scholar 

  3. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science 2001;291(5507):1304–1351.

    Article  CAS  Google Scholar 

  4. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature 2001;409(6822):860–921.

    Article  CAS  Google Scholar 

  5. Hagenbuch B, Meier PJ. The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 2003;1609(1):1–18.

    Article  CAS  Google Scholar 

  6. Satlin LM, Amin V, Wolkoff AW. Organic anion transporting polypeptide mediates organic anion/HCO3- exchange. J Biol Chem 1997;272(42):26340–26345.

    Article  CAS  Google Scholar 

  7. Li L, Lee TK, Meier PJ, Ballatori N. Identification of glutathione as a driving force and leukotriene C4 as a substrate for oatp1, the hepatic sinusoidal organic solute transporter. J Biol Chem 1998;273(26):16184–16191.

    Article  CAS  Google Scholar 

  8. Gao B, Stieger B, Noe B, Fritschy JM, Meier PJ. Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain. J Histochem Cytochem 1999;47(10):1255–1264.

    CAS  Google Scholar 

  9. Li L, Meier PJ, Ballatori N. Oatp2 mediates bidirectional organic solute transport: a role for intracellular glutathione. Mol Pharmacol 2000;58(2):335–340.

    CAS  Google Scholar 

  10. Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 2004;447(5):653–665.

    Article  CAS  Google Scholar 

  11. Shi X, Bai S, Ford AC, Burk RD, Jacquemin E, Hagenbuch B, et al. Stable inducible expression of a functional rat liver organic anion transport protein in HeLa cells. J Biol Chem 1995;270(43):25591–25595.

    Article  CAS  Google Scholar 

  12. Kullak-Ublick GA, Hagenbuch B, Stieger B, Schteingart CD, Hofmann AF, Wolkoff AW, et al. Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology 1995;109(4):1274–1282.

    Article  CAS  Google Scholar 

  13. Lee W, Glaeser H, Smith LH, Roberts RL, Moeckel GW, Gervasini G, et al. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J Biol Chem 2005;280(10):9610–9617.

    Article  CAS  Google Scholar 

  14. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 2000;273(1):251–260.

    Article  CAS  Google Scholar 

  15. Lee TK, Hammond CL, Ballatori N. Intracellular glutathione regulates taurocholate transport in HepG2 cells. Toxicol Appl Pharmacol 2001;174(3):207–215.

    Article  CAS  Google Scholar 

  16. Kullak-Ublick GA, Glasa J, Boker C, Oswald M, Grutzner U, Hagenbuch B, et al. Chlorambucil-taurocholate is transported by bile acid carriers expressed in human hepatocellular carcinomas. Gastroenterology 1997;113(4):1295–1305.

    Article  CAS  Google Scholar 

  17. Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, Meier PJ. Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Ther 2000;294(1):73–79.

    CAS  Google Scholar 

  18. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001;120(2):525–533.

    Article  CAS  Google Scholar 

  19. Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 2007;81(3):362–370.

    Article  CAS  Google Scholar 

  20. Nagase T, Ishikawa K, Suyama M, Kikuno R, Hirosawa M, Miyajima N, et al. Prediction of the coding sequences of unidentified human genes. XII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro. DNA Res 1998;5(6):355–364.

    Article  CAS  Google Scholar 

  21. St Pierre MV, Hagenbuch B, Ugele B, Meier PJ, Stallmach T. Characterization of an organic anion-transporting polypeptide (OATP-B) in human placenta. J Clin Endocrinol Metab 2002;87(4):1856–1863.

    Article  CAS  Google Scholar 

  22. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther 2003;306(2):703–708.

    Article  CAS  Google Scholar 

  23. Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther 2004;308(2):438–445.

    Article  CAS  Google Scholar 

  24. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 1999;274(52):37161–37168.

    Article  CAS  Google Scholar 

  25. Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, et al. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 1999;274(24):17159–17163.

    Article  CAS  Google Scholar 

  26. Konig J, Cui Y, Nies AT, Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 2000;278(1):G156-G164.

    CAS  Google Scholar 

  27. Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 2001;276(38):35669–35675.

    Article  CAS  Google Scholar 

  28. Abe T, Unno M, Onogawa T, Tokui T, Kondo TN, Nakagomi R, et al. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 2001;120(7):1689–1699.

    Article  CAS  Google Scholar 

  29. Konig J, Cui Y, Nies AT, Keppler D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 2000;275(30):23161–23168.

    Article  CAS  Google Scholar 

  30. Ismair MG, Stieger B, Cattori V, Hagenbuch B, Fried M, Meier PJ, et al. Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver. Gastroenterology 2001;121(5):1185–1190.

    Article  CAS  Google Scholar 

  31. Pizzagalli F, Hagenbuch B, Stieger B, Klenk U, Folkers G, Meier PJ. Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol 2002;16(10):2283–2296.

    Article  CAS  Google Scholar 

  32. Fujiwara K, Adachi H, Nishio T, Unno M, Tokui T, Okabe M, et al. Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology 2001;142(5):2005–2012.

    Article  CAS  Google Scholar 

  33. Sato K, Sugawara J, Sato T, Mizutamari H, Suzuki T, Ito A, et al. Expression of organic anion transporting polypeptide E (OATP-E) in human placenta. Placenta 2003;24(2–3):144–148.

    Article  CAS  Google Scholar 

  34. Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, et al. Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci USA 2004;101(10):3569–3574.

    Article  CAS  Google Scholar 

  35. Koepsell H, Endou H. The SLC22 drug transporter family. Pflugers Arch 2004;447(5):666–676.

    Article  CAS  Google Scholar 

  36. Koepsell H. Polyspecific organic cation transporters: their functions and interactions with drugs. Trends Pharmacol Sci 2004;25(7):375–381.

    Article  CAS  Google Scholar 

  37. Wright SH. Role of organic cation transporters in the renal handling of therapeutic agents and xenobiotics. Toxicol Appl Pharmacol 2005;204(3):309–319.

    Article  CAS  Google Scholar 

  38. Koepsell H, Schmitt BM, Gorboulev V. Organic cation transporters. Rev Physiol Biochem Pharmacol 2003;150:36–90.

    Article  CAS  Google Scholar 

  39. Grundemann D, Gorboulev V, Gambaryan S, Veyhl M, Koepsell H. Drug excretion mediated by a new prototype of polyspecific transporter. Nature 1994;372(6506):549–552.

    Article  CAS  Google Scholar 

  40. Dresser MJ, Leabman MK, Giacomini KM. Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. J Pharm Sci 2001;90(4):397–421.

    Article  CAS  Google Scholar 

  41. Barendt WM, Wright SH. The human organic cation transporter (hOCT2) recognizes the degree of substrate ionization. J Biol Chem 2002;277(25):22491–22496.

    Article  CAS  Google Scholar 

  42. Kimura H, Takeda M, Narikawa S, Enomoto A, Ichida K, Endou H. Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther 2002;301(1):293–298.

    Article  CAS  Google Scholar 

  43. Jonker JW, Wagenaar E, Mol CA, Buitelaar M, Koepsell H, Smit JW, et al. Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol Cell Biol 2001;21(16):5471–5477.

    Article  CAS  Google Scholar 

  44. Zwart R, Verhaagh S, Buitelaar M, Popp-Snijders C, Barlow DP. Impaired activity of the extraneuronal monoamine transporter system known as uptake-2 in Orct3/Slc22a3-deficient mice. Mol Cell Biol 2001;21(13):4188–4196.

    Article  CAS  Google Scholar 

  45. Jonker JW, Wagenaar E, Van Eijl S, Schinkel AH. Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol Cell Biol 2003;23(21):7902–7908.

    Article  CAS  Google Scholar 

  46. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 2002;302(2):510–515.

    Article  CAS  Google Scholar 

  47. Slitt AL, Cherrington NJ, Hartley DP, Leazer TM, Klaassen CD. Tissue distribution and renal developmental changes in rat organic cation transporter mRNA levels. Drug Metab Dispos 2002;30(2):212–219.

    Article  CAS  Google Scholar 

  48. Busch AE, Karbach U, Miska D, Gorboulev V, Akhoundova A, Volk C, et al. Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol 1998;54(2):342–352.

    CAS  Google Scholar 

  49. Beery E, Middel P, Bahn A, Willenberg HS, Hagos Y, Koepsell H, et al. Molecular evidence of organic ion transporters in the rat adrenal cortex with adrenocorticotropin-regulated zonal expression. Endocrinology 2003;144(10):4519–4526.

    Article  CAS  Google Scholar 

  50. Sweet DH, Miller DS, Pritchard JB. Ventricular choline transport: a role for organic cation transporter 2 expressed in choroid plexus. J Biol Chem 2001;276(45):41611–41619.

    Article  CAS  Google Scholar 

  51. Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, et al. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 1997;16(7):871–881.

    Article  CAS  Google Scholar 

  52. Motohashi H, Sakurai Y, Saito H, Masuda S, Urakami Y, Goto M, et al. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol 2002;13(4):866–874.

    CAS  Google Scholar 

  53. Karbach U, Kricke J, Meyer-Wentrup F, Gorboulev V, Volk C, Loffing-Cueni D, et al. Localization of organic cation transporters OCT1 and OCT2 in rat kidney. Am J Physiol Renal Physiol 2000;279(4):F679–F687.

    CAS  Google Scholar 

  54. Sugawara-Yokoo M, Urakami Y, Koyama H, Fujikura K, Masuda S, Saito H, et al. Differential localization of organic cation transporters rOCT1 and rOCT2 in the basolateral membrane of rat kidney proximal tubules. Histochem Cell Biol 2000;114(3):175–180.

    CAS  Google Scholar 

  55. Urakami Y, Akazawa M, Saito H, Okuda M, Inui K. cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol 2002;13(7):1703–1710.

    Article  CAS  Google Scholar 

  56. Shang T, Uihlein AV, Van Asten J, Kalyanaraman B, Hillard CJ. 1-Methyl-4-phenylpyridinium accumulates in cerebellar granule neurons via organic cation transporter 3. J Neurochem 2003;85(2):358–367.

    Article  CAS  Google Scholar 

  57. Kristufek D, Rudorfer W, Pifl C, Huck S. Organic cation transporter mRNA and function in the rat superior cervical ganglion. J Physiol 2002;543(Pt 1):117–134.

    Article  CAS  Google Scholar 

  58. Inazu M, Takeda H, Matsumiya T. Expression and functional characterization of the extraneuronal monoamine transporter in normal human astrocytes. J Neurochem 2003;84(1):43–52.

    Article  CAS  Google Scholar 

  59. Haag C, Berkels R, Grundemann D, Lazar A, Taubert D, Schomig E. The localisation of the extraneuronal monoamine transporter (EMT) in rat brain. J Neurochem 2004;88(2):291–297.

    Article  CAS  Google Scholar 

  60. Pritchard JB, Miller DS. Mechanisms mediating renal secretion of organic anions and cations. Physiol Rev 1993;73(4):765–796.

    CAS  Google Scholar 

  61. Moller JV, Sheikh MI. Renal organic anion transport system: pharmacological, physiological, and biochemical aspects. Pharmacol Rev 1982;34(4):315–358.

    CAS  Google Scholar 

  62. Ullrich KJ. Renal transporters for organic anions and organic cations. Structural requirements for substrates. J Membr Biol 1997;158(2):95–107.

    Article  CAS  Google Scholar 

  63. Sekine T, Watanabe N, Hosoyamada M, Kanai Y, Endou H. Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem 1997;272(30):18526–18529.

    Article  CAS  Google Scholar 

  64. Sweet DH, Wolff NA, Pritchard JB. Expression cloning and characterization of ROAT1. The basolateral organic anion transporter in rat kidney. J Biol Chem 1997;272(48):30088–30095.

    Article  CAS  Google Scholar 

  65. Wolff NA, Werner A, Burkhardt S, Burckhardt G. Expression cloning and characterization of a renal organic anion transporter from winter flounder. FEBS Lett 1997;417(3):287–291.

    Article  CAS  Google Scholar 

  66. Shimada H, Moewes B, Burckhardt G. Indirect coupling to Na+ of p-aminohippuric acid uptake into rat renal basolateral membrane vesicles. Am J Physiol 1987;253(5 Pt 2):F795–F801.

    CAS  Google Scholar 

  67. Miyazaki H, Sekine T, Endou H. The multispecific organic anion transporter family: properties and pharmacological significance. Trends Pharmacol Sci 2004;25(12):654–662.

    Article  CAS  Google Scholar 

  68. Eraly SA, Vallon V, Vaughn DA, Gangoiti JA, Richter K, Nagle M, et al. Decreased renal organic anion secretion and plasma accumulation of endogenous organic anions in OAT1 knockout mice. J Biol Chem 2006;281:5072–5083.

    Google Scholar 

  69. Simonson GD, Vincent AC, Roberg KJ, Huang Y, Iwanij V. Molecular cloning and characterization of a novel liver-specific transport protein. J Cell Sci 1994;107(Pt 4):1065–1072.

    CAS  Google Scholar 

  70. Kobayashi Y, Ohshiro N, Sakai R, Ohbayashi M, Kohyama N, Yamamoto T. Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol 2005;57(5):573–578.

    Article  CAS  Google Scholar 

  71. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, et al. Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem 1999;274(19):13675–13680.

    Article  CAS  Google Scholar 

  72. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, et al. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol 2001;59(5):1277–1286.

    CAS  Google Scholar 

  73. Nagata Y, Kusuhara H, Endou H, Sugiyama Y. Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus. Mol Pharmacol 2002;61(5):982–988.

    Article  CAS  Google Scholar 

  74. Sweet DH, Miller DS, Pritchard JB, Fujiwara Y, Beier DR, Nigam SK. Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J Biol Chem 2002;277(30):26934–26943.

    Article  CAS  Google Scholar 

  75. Ohtsuki S, Kikkawa T, Mori S, Hori S, Takanaga H, Otagiri M, et al. Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. J Pharmacol Exp Ther 2004;309(3):1273–1281.

    Article  CAS  Google Scholar 

  76. Sweet DH, Chan LM, Walden R, Yang XP, Miller DS, Pritchard JB. Organic anion transporter 3 (Slc22a8) is a dicarboxylate exchanger indirectly coupled to the Na+ gradient. Am J Physiol Renal Physiol 2003;284(4):F763-F769.

    CAS  Google Scholar 

  77. Bakhiya A, Bahn A, Burckhardt G, Wolff N. Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux. Cell Physiol Biochem 2003;13(5):249–256.

    Article  CAS  Google Scholar 

  78. Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, et al. Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem 2000;275(6):4507–4512.

    Article  CAS  Google Scholar 

  79. Ugele B, St Pierre MV, Pihusch M, Bahn A, Hantschmann P. Characterization and identification of steroid sulfate transporters of human placenta. Am J Physiol Endocrinol Metab 2003;284(2):E390-E398.

    CAS  Google Scholar 

  80. Ekaratanawong S, Anzai N, Jutabha P, Miyazaki H, Noshiro R, Takeda M, et al. Human organic anion transporter 4 is a renal apical organic anion/dicarboxylate exchanger in the proximal tubules. J Pharmacol Sci 2004;94(3):297–304.

    Article  CAS  Google Scholar 

  81. Klein I, Sarkadi B, Varadi A. An inventory of the human ABC proteins. Biochim Biophys Acta 1999;1461(2):237–262.

    Article  CAS  Google Scholar 

  82. Dean M, Allikmets R. Complete characterization of the human ABC gene family. J Bioenerg Biomembr 2001;33(6):475–479.

    Article  CAS  Google Scholar 

  83. Sarkadi B, Ozvegy-Laczka C, Nemet K, Varadi A. ABCG2 – a transporter for all seasons. FEBS Lett 2004;567(1):116–120.

    Article  CAS  Google Scholar 

  84. Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005;204(3):216–237.

    Article  CAS  Google Scholar 

  85. Walker JE, Saraste M, Runswick MJ, Gay NJ. Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J 1982;1(8):945–951.

    CAS  Google Scholar 

  86. Hung LW, Wang IX, Nikaido K, Liu PQ, Ames GF, Kim SH. Crystal structure of the ATP-binding subunit of an ABC transporter. Nature 1998;396(6712):703–707.

    Article  CAS  Google Scholar 

  87. Sharom FJ, Liu R, Romsicki Y, Lu P. Insights into the structure and substrate interactions of the P-glycoprotein multidrug transporter from spectroscopic studies. Biochim Biophys Acta 1999;1461(2):327–345.

    Article  CAS  Google Scholar 

  88. Lepper ER, Nooter K, Verweij J, Acharya MR, Figg WD, Sparreboom A. Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics 2005;6(2):115–138.

    Article  CAS  Google Scholar 

  89. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455(1):152–162.

    Article  CAS  Google Scholar 

  90. Chan LM, Lowes S, Hirst BH. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 2004;21(1):25–51.

    Article  CAS  Google Scholar 

  91. Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 2002;34(1–2):47–54.

    Article  CAS  Google Scholar 

  92. van Asperen J, van Tellingen O, Beijnen JH. The pharmacological role of P-glycoprotein in the intestinal epithelium. Pharmacol Res 1998;37(6):429–435.

    Article  Google Scholar 

  93. Schinkel AH. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 1997;8(3):161–170.

    Article  CAS  Google Scholar 

  94. Schellens JH, Malingre MM, Kruijtzer CM, Bardelmeijer HA, van Tellingen O, Schinkel AH, et al. Modulation of oral bioavailability of anticancer drugs: from mouse to man. Eur J Pharm Sci 2000;12(2):103–110.

    Article  CAS  Google Scholar 

  95. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77(4):491–502.

    Article  CAS  Google Scholar 

  96. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 1997;94(8):4028–4033.

    Article  CAS  Google Scholar 

  97. Gatmaitan ZC, Arias IM. Structure and function of P-glycoprotein in normal liver and small intestine. Adv Pharmacol 1993;24:77–97.

    Article  CAS  Google Scholar 

  98. Guengerich FP. Human cytochrome P450 enzymes. In:Ortiz de Montellano P, ed. Cytochrome P450. New York: Plenum Press, 1995:473–535.

    Google Scholar 

  99. Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996;49(2):311–318.

    CAS  Google Scholar 

  100. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999;16(3):408–414.

    Article  CAS  Google Scholar 

  101. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84(21):7735–7738.

    Article  CAS  Google Scholar 

  102. Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 1997;27(2–3):161–170.

    Article  CAS  Google Scholar 

  103. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998;95(26):15665–15670.

    Article  CAS  Google Scholar 

  104. Chen YN, Mickley LA, Schwartz AM, Acton EM, Hwang JL, Fojo AT. Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem 1990;265(17):10073–10080.

    CAS  Google Scholar 

  105. Lee JS, Scala S, Matsumoto Y, Dickstein B, Robey R, Zhan Z, et al. Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression. J Cell Biochem 1997;65(4):513–526.

    Article  CAS  Google Scholar 

  106. Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, Varadi A, et al. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun 2001;285(1):111–117.

    Article  CAS  Google Scholar 

  107. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003;55(1):3–29.

    Article  CAS  Google Scholar 

  108. Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, van de LA, et al. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 2001;61(18):6635–6639.

    CAS  Google Scholar 

  109. Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001;58(7):931–959.

    Article  CAS  Google Scholar 

  110. Volk EL, Farley KM, Wu Y, Li F, Robey RW, Schneider E. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res 2002;62(17):5035–5040.

    CAS  Google Scholar 

  111. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001;7(9):1028–1034.

    Article  CAS  Google Scholar 

  112. Jonker JW, Buitelaar M, Wagenaar E, van der Valk MA, Scheffer GL, Scheper RJ, et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 2002;99(24):15649–15654.

    Article  CAS  Google Scholar 

  113. van Herwaarden AE, Jonker JW, Wagenaar E, Brinkhuis RF, Schellens JH, Beijnen JH, et al. The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Res 2003;63(19):6447–6452.

    Google Scholar 

  114. Robey RW, Steadman K, Polgar O, Morisaki K, Blayney M, Mistry P, et al. Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res 2004;64(4):1242–1246.

    Article  CAS  Google Scholar 

  115. Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, Sugiyama Y. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 2005;68(3):800–807.

    CAS  Google Scholar 

  116. Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H, et al. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 1999;91(5):429–433.

    Article  CAS  Google Scholar 

  117. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999;59(18):4559–4563.

    CAS  Google Scholar 

  118. Kawabata S, Oka M, Shiozawa K, Tsukamoto K, Nakatomi K, Soda H, et al. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun 2001;280(5):1216–1223.

    Article  CAS  Google Scholar 

  119. Komatani H, Kotani H, Hara Y, Nakagawa R, Matsumoto M, Arakawa H, et al. Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. Cancer Res 2001;61(7):2827–2832.

    CAS  Google Scholar 

  120. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001;61(8):3458–3464.

    CAS  Google Scholar 

  121. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 2000;92(20):1651–1656.

    Article  CAS  Google Scholar 

  122. Childs S, Yeh RL, Georges E, Ling V. Identification of a sister gene to P-glycoprotein. Cancer Res 1995;55(10):2029–2034.

    CAS  Google Scholar 

  123. Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J, et al. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem 1998;273(16):10046–10050.

    Article  CAS  Google Scholar 

  124. Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology 2002;123(5):1649–1658.

    Article  CAS  Google Scholar 

  125. Noe J, Stieger B, Meier PJ. Functional expression of the canalicular bile salt export pump of human liver. Gastroenterology 2002;123(5):1659–1666.

    Article  CAS  Google Scholar 

  126. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, et al. Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol 2000;57(1):24–35.

    CAS  Google Scholar 

  127. Hirano M, Maeda K, Hayashi H, Kusuhara H, Sugiyama Y. Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J Pharmacol Exp Ther 2005;314(2):876–882.

    Article  CAS  Google Scholar 

  128. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 2001;69(4):223–231.

    Article  CAS  Google Scholar 

  129. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 2000;118(2):422–430.

    Article  CAS  Google Scholar 

  130. Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 2004;126(1):322–342.

    Article  CAS  Google Scholar 

  131. Meier PJ. Canalicular bile formation: beyond single transporter functions. J Hepatol 2002;37(2):272–273.

    Article  Google Scholar 

  132. Crocenzi FA, Mottino AD, Cao J, Veggi LM, Pozzi EJ, Vore M, et al. Estradiol-17beta-D-glucuronide induces endocytic internalization of Bsep in rats. Am J Physiol Gastrointest Liver Physiol 2003;285(2):G449-G459.

    CAS  Google Scholar 

  133. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258(5088):1650–1654.

    Article  CAS  Google Scholar 

  134. Cherrington NJ, Hartley DP, Li N, Johnson DR, Klaassen CD. Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. J Pharmacol Exp Ther 2002;300(1):97–104.

    Article  CAS  Google Scholar 

  135. Flens MJ, Zaman GJ, van d, V, Izquierdo MA, Schroeijers AB, Scheffer GL, et al. Tissue distribution of the multidrug resistance protein. Am J Pathol 1996;148(4):1237–1247.

    CAS  Google Scholar 

  136. Zaman GJ, Versantvoort CH, Smit JJ, Eijdems EW, de Haas M, Smith AJ, et al. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res 1993;53(8):1747–1750.

    CAS  Google Scholar 

  137. Zhang Y, Han H, Elmquist WF, Miller DW. Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells. Brain Res 2000;876(1–2):148–153.

    Article  CAS  Google Scholar 

  138. Peng KC, Cluzeaud F, Bens M, Van Huyen JP, Wioland MA, Lacave R, et al. Tissue and cell distribution of the multidrug resistance-associated protein (MRP) in mouse intestine and kidney. J Histochem Cytochem 1999;47(6):757–768.

    CAS  Google Scholar 

  139. Mayer R, Kartenbeck J, Buchler M, Jedlitschky G, Leier I, Keppler D. Expression of the MRP gene-encoded conjugate export pump in liver and its selective absence from the canalicular membrane in transport-deficient mutant hepatocytes. J Cell Biol 1995;131(1):137–150.

    Article  CAS  Google Scholar 

  140. Roelofsen H, Vos TA, Schippers IJ, Kuipers F, Koning H, Moshage H, et al. Increased levels of the multidrug resistance protein in lateral membranes of proliferating hepatocyte-derived cells. Gastroenterology 1997;112(2):511–521.

    Article  CAS  Google Scholar 

  141. Cole SP, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 1994;54(22):5902–5910.

    CAS  Google Scholar 

  142. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SP, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994;54(2):357–361.

    CAS  Google Scholar 

  143. Stride BD, Grant CE, Loe DW, Hipfner DR, Cole SP, Deeley RG. Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells. Mol Pharmacol 1997;52(3):344–353.

    CAS  Google Scholar 

  144. Zaman GJ, Flens MJ, van Leusden MR, de Haas M, Mulder HS, Lankelma J, et al. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 1994;91(19):8822–8826.

    Article  CAS  Google Scholar 

  145. Leier I, Jedlitschky G, Buchholz U, Cole SP, Deeley RG, Keppler D. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem 1994;269(45):27807–27810.

    CAS  Google Scholar 

  146. Muller M, Meijer C, Zaman GJ, Borst P, Scheper RJ, Mulder NH, et al. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA 1994;91(26):13033–13037.

    Article  CAS  Google Scholar 

  147. Evers R, Zaman GJ, van Deemter L, Jansen H, Calafat J, Oomen LC, et al. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J Clin Invest 1996;97(5):1211–1218.

    Article  CAS  Google Scholar 

  148. Loe DW, Almquist KC, Cole SP, Deeley RG. ATP-dependent 17 beta-estradiol 17-(beta-D-glucuronide) transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids. J Biol Chem 1996;271(16):9683–9689.

    Article  CAS  Google Scholar 

  149. Rappa G, Lorico A, Flavell RA, Sartorelli AC. Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins. Cancer Res 1997;57(23):5232–5237.

    CAS  Google Scholar 

  150. Loe DW, Deeley RG, Cole SP. Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res 1998;58(22):5130–5136.

    CAS  Google Scholar 

  151. Jedlitschky G, Leier I, Buchholz U, Barnouin K, Kurz G, Keppler D. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res 1996;56(5):988–994.

    CAS  Google Scholar 

  152. Jedlitschky G, Leier I, Buchholz U, Hummel-Eisenbeiss J, Burchell B, Keppler D. ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2. Biochem J 1997;327(Pt 1):305–310.

    CAS  Google Scholar 

  153. Leier I, Jedlitschky G, Buchholz U, Center M, Cole SP, Deeley RG, et al. ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump. Biochem J 1996;314(Pt 2):433–437.

    CAS  Google Scholar 

  154. Pei QL, Kobayashi Y, Tanaka Y, Taguchi Y, Higuchi K, Kaito M, et al. Increased expression of multidrug resistance-associated protein 1 (mrp1) in hepatocyte basolateral membrane and renal tubular epithelia after bile duct ligation in rats. Hepatol Res 2002;22(1):58–64.

    Article  CAS  Google Scholar 

  155. Wijnholds J, Evers R, van Leusden MR, Mol CA, Zaman GJ, Mayer U, et al. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat Med 1997;3(11):1275–1279.

    Article  CAS  Google Scholar 

  156. Lorico A, Rappa G, Finch RA, Yang D, Flavell RA, Sartorelli AC. Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione. Cancer Res 1997;57(23):5238–5242.

    CAS  Google Scholar 

  157. Robbiani DF, Finch RA, Jager D, Muller WA, Sartorelli AC, Randolph GJ. The leukotriene C (4) transporter MRP1 regulates CCL19 (MIP-3beta, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell 2000;103(5):757–768.

    Article  CAS  Google Scholar 

  158. Wijnholds J, Scheffer GL, van d, V, van d, V, Beijnen JH, Scheper RJ, et al. Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage. J Exp Med 1998;188(5):797–808.

    Article  CAS  Google Scholar 

  159. Tada Y, Wada M, Migita T, Nagayama J, Hinoshita E, Mochida Y, et al. Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin. Int J Cancer 2002;98(4):630–635.

    Article  CAS  Google Scholar 

  160. Johnson DR, Finch RA, Lin ZP, Zeiss CJ, Sartorelli AC. The pharmacological phenotype of combined multidrug-resistance mdr1a/1b- and mrp1-deficient mice. Cancer Res 2001;61(4):1469–1476.

    CAS  Google Scholar 

  161. Leslie EM, Deeley RG, Cole SP. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 2001;167(1):3–23.

    Article  CAS  Google Scholar 

  162. Paulusma CC, Bosma PJ, Zaman GJ, Bakker CT, Otter M, Scheffer GL, et al. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 1996;271(5252):1126–1128.

    Article  CAS  Google Scholar 

  163. Fromm MF, Kauffmann HM, Fritz P, Burk O, Kroemer HK, Warzok RW, et al. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 2000;157(5):1575–1580.

    CAS  Google Scholar 

  164. Schaub TP, Kartenbeck J, Konig J, Vogel O, Witzgall R, Kriz W, et al. Expression of the conjugate export pump encoded by the mrp2 gene in the apical membrane of kidney proximal tubules. J Am Soc Nephrol 1997;8(8):1213–1221.

    CAS  Google Scholar 

  165. Scheffer GL, Kool M, de Haas M, de Vree JM, Pijnenborg AC, Bosman DK, et al. Tissue distribution and induction of human multidrug resistant protein 3. Lab Invest 2002;82(2):193–201.

    CAS  Google Scholar 

  166. Kawabe T, Chen ZS, Wada M, Uchiumi T, Ono M, Akiyama S, et al. Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2). FEBS Lett 1999;456(2):327–331.

    Article  CAS  Google Scholar 

  167. Madon J, Eckhardt U, Gerloff T, Stieger B, Meier PJ. Functional expression of the rat liver canalicular isoform of the multidrug resistance-associated protein. FEBS Lett 1997;406(1–2):75–78.

    Article  CAS  Google Scholar 

  168. Paulusma CC, Kool M, Bosma PJ, Scheffer GL, ter Borg F, Scheper RJ, et al. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 1997;25(6):1539–1542.

    Article  CAS  Google Scholar 

  169. Paulusma CC, Oude Elferink RP. The canalicular multispecific organic anion transporter and conjugated hyperbilirubinemia in rat and man. J Mol Med 1997;75(6):420–428.

    Article  CAS  Google Scholar 

  170. Buchler M, Konig J, Brom M, Kartenbeck J, Spring H, Horie T, et al. cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J Biol Chem 1996;271(25):15091–15098.

    Article  CAS  Google Scholar 

  171. Yamazaki K, Mikami T, Hosokawa S, Tagaya O, Nozaki Y, Kawaguchi A, et al. A new mutant rat with hyperbilirubinuria (hyb). J Hered 1995;86(4):314–317.

    CAS  Google Scholar 

  172. Ballatori N, Gatmaitan Z, Truong AT. Impaired biliary excretion and whole body elimination of methylmercury in rats with congenital defect in biliary glutathione excretion. Hepatology 1995;22(5):1469–1473.

    CAS  Google Scholar 

  173. Keitel V, Nies AT, Brom M, Hummel-Eisenbeiss J, Spring H, Keppler D. A common Dubin-Johnson syndrome mutation impairs protein maturation and transport activity of MRP2 (ABCC2). Am J Physiol Gastrointest Liver Physiol 2003;284(1):G165-G174.

    CAS  Google Scholar 

  174. Paulusma CC, van Geer MA, Evers R, Heijn M, Ottenhoff R, Borst P, et al. Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione. Biochem J 1999;338(Pt 2):393–401.

    Article  CAS  Google Scholar 

  175. Evers R, Kool M, van Deemter L, Janssen H, Calafat J, Oomen LC, et al. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Invest 1998;101(7):1310–1319.

    CAS  Google Scholar 

  176. Cui Y, Konig J, Buchholz JK, Spring H, Leier I, Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 1999;55(5):929–937.

    CAS  Google Scholar 

  177. Koike K, Kawabe T, Tanaka T, Toh S, Uchiumi T, Wada M, et al. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res 1997;57(24):5475–5479.

    CAS  Google Scholar 

  178. Gutmann H, Fricker G, Drewe J, Toeroek M, Miller DS. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 1999;56(2):383–389.

    CAS  Google Scholar 

  179. Huisman MT, Smit JW, Crommentuyn KM, Zelcer N, Wiltshire HR, Beijnen JH, et al. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 2002;16(17):2295–2301.

    Article  CAS  Google Scholar 

  180. Miller DS. Nucleoside phosphonate interactions with multiple organic anion transporters in renal proximal tubule. J Pharmacol Exp Ther 2001;299(2):567–574.

    CAS  Google Scholar 

  181. Naruhashi K, Tamai I, Inoue N, Muraoka H, Sai Y, Suzuki N, et al. Involvement of multidrug resistance-associated protein 2 in intestinal secretion of grepafloxacin in rats. Antimicrob Agents Chemother 2002;46(2):344–349.

    Article  CAS  Google Scholar 

  182. Walgren RA, Karnaky KJ, Jr., Lindenmayer GE, Walle T. Efflux of dietary flavonoid quercetin 4′-beta-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistance-associated protein-2. J Pharmacol Exp Ther 2000;294(3):830–836.

    CAS  Google Scholar 

  183. Vaidyanathan JB, Walle T. Transport and metabolism of the tea flavonoid (-)-epicatechin by the human intestinal cell line Caco-2. Pharm Res 2001;18(10):1420–1425.

    Article  CAS  Google Scholar 

  184. Belinsky MG, Kruh GD. MOAT-E (ARA) is a full-length MRP/cMOAT subfamily transporter expressed in kidney and liver. Br J Cancer 1999;80(9):1342–1349.

    Article  CAS  Google Scholar 

  185. Kiuchi Y, Suzuki H, Hirohashi T, Tyson CA, Sugiyama Y. cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3). FEBS Lett 1998;433(1–2):149–152.

    Article  CAS  Google Scholar 

  186. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 1997;57(16):3537–3547.

    CAS  Google Scholar 

  187. Kool M, van der LM, de Haas M, Scheffer GL, de Vree JM, Smith AJ, et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 1999;96(12):6914–6919.

    Article  CAS  Google Scholar 

  188. Hirohashi T, Suzuki H, Takikawa H, Sugiyama Y. ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3). J Biol Chem 2000;275(4):2905–2910.

    Article  CAS  Google Scholar 

  189. Zeng H, Liu G, Rea PA, Kruh GD. Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res 2000;60(17):4779–4784.

    CAS  Google Scholar 

  190. Zeng H, Bain LJ, Belinsky MG, Kruh GD. Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res 1999;59(23):5964–5967.

    CAS  Google Scholar 

  191. Zelcer N, Saeki T, Reid G, Beijnen JH, Borst P. Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem 2001;276(49):46400–46407.

    Article  CAS  Google Scholar 

  192. Konig J, Rost D, Cui Y, Keppler D. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology 1999;29(4):1156–1163.

    Article  CAS  Google Scholar 

  193. Hirohashi T, Suzuki H, Ito K, Ogawa K, Kume K, Shimizu T, et al. Hepatic expression of multidrug resistance-associated protein-like proteins maintained in eisai hyperbilirubinemic rats. Mol Pharmacol 1998;53(6):1068–1075.

    CAS  Google Scholar 

  194. Taipalensuu J, Tornblom H, Lindberg G, Einarsson C, Sjoqvist F, Melhus H, et al. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther 2001;299(1):164–170.

    CAS  Google Scholar 

  195. Van Aubel RA, Smeets PH, Peters JG, Bindels RJ, Russel FG. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 2002;13(3):595–603.

    Google Scholar 

  196. Lee K, Klein-Szanto AJ, Kruh GD. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J Natl Cancer Inst 2000;92(23):1934–1940.

    Article  CAS  Google Scholar 

  197. Lai L, Tan TM. Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. Biochem J 2002;361(Pt 3):497–503.

    Article  CAS  Google Scholar 

  198. Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, et al. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res 2002;62(11):3144–3150.

    CAS  Google Scholar 

  199. Chen ZS, Lee K, Kruh GD. Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem 2001;276(36):33747–33754.

    Article  CAS  Google Scholar 

  200. Zelcer N, Reid G, Wielinga P, Kuil A, van dH, I, Schuetz JD, et al. Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J 2003;371(Pt 2):361–367.

    Article  CAS  Google Scholar 

  201. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, et al. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 1999;5(9):1048–1051.

    Article  CAS  Google Scholar 

  202. Belinsky MG, Bain LJ, Balsara BB, Testa JR, Kruh GD. Characterization of MOAT-C and MOAT-D, new members of the MRP/cMOAT subfamily of transporter proteins. J Natl Cancer Inst 1998;90(22):1735–1741.

    Article  CAS  Google Scholar 

  203. McAleer MA, Breen MA, White NL, Matthews N. pABC11 (also known as MOAT-C and MRP5), a member of the ABC family of proteins, has anion transporter activity but does not confer multidrug resistance when overexpressed in human embryonic kidney 293 cells. J Biol Chem 1999;274(33):23541–23548.

    Article  CAS  Google Scholar 

  204. Wijnholds J, Mol CA, van Deemter L, de Haas M, Scheffer GL, Baas F, et al. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA 2000;97(13):7476–7481.

    Article  CAS  Google Scholar 

  205. Nies AT, Jedlitschky G, Konig J, Herold-Mende C, Steiner HH, Schmitt HP, et al. Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience 2004;129(2):349–360.

    Article  CAS  Google Scholar 

  206. Wielinga P, Hooijberg JH, Gunnarsdottir S, Kathmann I, Reid G, Zelcer N, et al. The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res 2005;65(10):4425–4430.

    Article  CAS  Google Scholar 

  207. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 1997;94(5):2031–2035.

    Article  CAS  Google Scholar 

  208. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995;96(4):1698–1705.

    Article  CAS  Google Scholar 

  209. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101(2):289–294.

    Article  CAS  Google Scholar 

  210. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997;62(3):248–260.

    Article  CAS  Google Scholar 

  211. Drescher S, Glaeser H, Murdter T, Hitzl M, Eichelbaum M, Fromm MF. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther 2003;73(3):223–231.

    Article  CAS  Google Scholar 

  212. Nakai D, Nakagomi R, Furuta Y, Tokui T, Abe T, Ikeda T, et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther 2001;297(3):861–867.

    CAS  Google Scholar 

  213. You G. Structure, Function, and Regulation of Renal Organic Anion Transporters. Medicinal Research Reviews 2002;22(6):602–616.

    Article  CAS  Google Scholar 

  214. Lee G, Dallas S, Hong M, Bendayan R. Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol Rev 2001;53(4):569–596.

    CAS  Google Scholar 

  215. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989;86(2):695–698.

    Article  CAS  Google Scholar 

  216. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine [see comments]. Circulation 1999;99(4):552–557.

    CAS  Google Scholar 

  217. Yokogawa K, Takahashi M, Tamai I, Konishi H, Nomura M, Moritani S, et al. P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr1a knockout mice. Pharm Res 1999;16(8):1213–1218.

    Article  CAS  Google Scholar 

  218. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000;356(9242):1667–1671.

    Article  CAS  Google Scholar 

  219. Conseil G, Deeley RG, Cole SPC. Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. Pharmacogen Genomics 2005;15:523–533.

    Google Scholar 

  220. Cervenak J, Andrikovics H, Ozvegy-Laczka C, et al. The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology. Cancer Lett 2006;234:62–72.

    Google Scholar 

  221. Kioka N, Tsubota J, Kakehi Y, Komano T, Gottesman MM, Pastan I, et al. P-glycoprotein gene (MDR1) cDNA from human adrenal: normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance. Biochem Biophys Res Commun 1989;162(1):224–231.

    Article  CAS  Google Scholar 

  222. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97(7):3473–3478.

    Article  CAS  Google Scholar 

  223. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, et al. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 2007;315(5811):525–528.

    Article  CAS  Google Scholar 

  224. Siegsmund M, Brinkmann U, Schaffeler E, Weirich G, Schwab M, Eichelbaum M, et al. Association of the P-glycoprotein transporter MDR1C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002;13(7):1847–1854.

    Article  CAS  Google Scholar 

  225. Drozdzik M, Bialecka M, Mysliwiec K, Honczarenko K, Stankiewicz J, Sych Z. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 2003;13(5):259–263.

    Article  CAS  Google Scholar 

  226. Schwab M, Schaeffeler E, Marx C, Fromm MF, Kaskas B, Metzler J, et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003;124(1):26–33.

    Article  CAS  Google Scholar 

  227. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003;348(15):1442–1448.

    Article  CAS  Google Scholar 

  228. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002;359(9300):30–36.

    Article  CAS  Google Scholar 

  229. Leschziner GD, Andrew T, Pirmohamed M, Johnson MR. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenom J 2007;7:154–179.

    Google Scholar 

  230. Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, et al. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 2002;302(2):804–813.

    Article  CAS  Google Scholar 

  231. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 2003;73(6):554–565.

    Article  CAS  Google Scholar 

  232. Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 2004;75(5):415–421.

    Article  CAS  Google Scholar 

  233. Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004;14(7):429–440.

    Article  CAS  Google Scholar 

  234. Ho RH, Choi L, Lee W, Mayo G, Schwarz UI, Tirona RG, et al. Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet Genomics 2007;17(8):647–656.

    Article  CAS  Google Scholar 

  235. Tirona RG, Kim RB. Pharmacogenomics of organic anion-transporting polypeptides (OATP). Adv Drug Deliv Rev 2002;54(10):1343–1352.

    Article  CAS  Google Scholar 

  236. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 2003;4(4):397–410.

    Article  CAS  Google Scholar 

  237. Pauli-Magnus C, Meier PJ. Pharmacogenetics of hepatocellular transporters. Pharmacogenetics 2003;13(4):189–198.

    Article  CAS  Google Scholar 

  238. Bohan A, Boyer JL. Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions. Semin Liver Dis 2002;22(2):123–136.

    Article  CAS  Google Scholar 

  239. Lockhart AC, Tirona RG, Kim RB. Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther 2003;2(7):685–698.

    CAS  Google Scholar 

  240. Suzuki H, Sugiyama Y. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv Drug Deliv Rev 2002;54(10):1311–1331.

    Article  CAS  Google Scholar 

  241. Jankel CA, Fitterman LK. Epidemiology of drug-drug interactions as a cause of hospital admissions. Drug Saf 1993;9(1):51–59.

    Article  CAS  Google Scholar 

  242. Handschin C, Meyer UA. Induction of drug metabolism: the role of nuclear receptors. Pharmacol Rev 2003;55(4):649–673.

    Article  CAS  Google Scholar 

  243. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995;83(6):841–850.

    Article  CAS  Google Scholar 

  244. Goodwin B, Moore LB, Stoltz CM, McKee DD, Kliewer SA. Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol 2001;60(3):427–431.

    CAS  Google Scholar 

  245. Goodwin B, Hodgson E, Liddle C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 1999;56(6):1329–1339.

    CAS  Google Scholar 

  246. Wang H, Faucette S, Sueyoshi T, Moore R, Ferguson S, Negishi M, et al. A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J Biol Chem 2003;278(16):14146–14152.

    Article  CAS  Google Scholar 

  247. Chen Y, Ferguson SS, Negishi M, Goldstein JA. Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J Pharmacol Exp Ther 2004;308(2):495–501.

    Article  CAS  Google Scholar 

  248. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001;276(18):14581–14587.

    Article  CAS  Google Scholar 

  249. Urquhart BL, Tirona RG, Kim RB. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J Clin Pharmacol 2007;47(5):566–578.

    Article  CAS  Google Scholar 

  250. Tirona RG, Kim RB. Nuclear receptors and drug disposition gene regulation. J Pharm Sci 2005;94(6):1169–1186.

    Article  CAS  Google Scholar 

  251. Eloranta JJ, Kullak-Ublick GA. Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. Arch Biochem Biophys 2005;433(2):397–412.

    Article  CAS  Google Scholar 

  252. Wakasugi H, Yano I, Ito T, Hashida T, Futami T, Nohara R, et al. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther 1998;64(1):123–128.

    Article  CAS  Google Scholar 

  253. Westphal K, Weinbrenner A, Giessmann T, Stuhr M, Franke G, Zschiesche M, et al. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther 2000;68(1):6–12.

    Article  CAS  Google Scholar 

  254. Boyd RA, Stern RH, Stewart BH, Wu X, Reyner EL, Zegarac EA, et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 2000;40(1):91–98.

    Article  CAS  Google Scholar 

  255. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999;104(2):147–153.

    Article  CAS  Google Scholar 

  256. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996;97(11):2517–2524.

    Article  CAS  Google Scholar 

  257. Sadeque AJ, Wandel C, He H, Shah S, Wood AJ. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 2000;68(3):231–237.

    Article  CAS  Google Scholar 

  258. Burnell JM, Kirby WMM. Effectiveness of a New Compound Benemid, in Elevating Serum Penicillin Concentrations. J Clin Invest 1951;30:697–700.

    Article  CAS  Google Scholar 

  259. Jariyawat S, Sekine T, Takeda M, Apiwattanakul N, Kanai Y, Sophasan S, et al. The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther 1999;290(2):672–677.

    CAS  Google Scholar 

  260. Ayrton A, Morgan P. Role of Transport Proteins in Drug Absorption, Distribution, and Excretion. Xenobiotica 2001;31(8/9):469–497.

    Article  CAS  Google Scholar 

  261. Shen DD, Azarnoff DL. Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet 1978;3(1):1–13.

    Article  CAS  Google Scholar 

  262. Basin KS, Escalante A, Beardmore TD. Severe pancytopenia in a patient taking low dose methotrexate and probenecid. J Rheumatol 1991;18(4):609–610.

    CAS  Google Scholar 

  263. Ellison NM, Servi RJ. Acute renal failure and death following sequential intermediate-dose methotrexate and 5-FU: a possible adverse effect due to concomitant indomethacin administration. Cancer Treat Rep 1985;69(3):342–343.

    CAS  Google Scholar 

  264. Thyss A, Milano G, Kubar J, Namer M, Schneider M. Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet 1986;1(8475):256–258.

    Article  CAS  Google Scholar 

  265. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, et al. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther 2002;302(2):666–671.

    Article  CAS  Google Scholar 

  266. Bailey DG, Spence JD, Munoz C, Arnold JM. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991;337(8736):268–269.

    Article  CAS  Google Scholar 

  267. Guengerich FP, Brian WR, Iwasaki M, Sari MA, Baarnhielm C, Berntsson P. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J Med Chem 1991;34(6):1838–1844.

    Article  CAS  Google Scholar 

  268. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997;99(10):2545–2553.

    Article  CAS  Google Scholar 

  269. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002;71(1):11–20.

    Article  CAS  Google Scholar 

  270. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279(15):1200–1205.

    Article  CAS  Google Scholar 

  271. Spivey JR, Bronk SF, Gores GJ. Glycochenodeoxycholate-induced lethal hepatocellular injury in rat hepatocytes. Role of ATP depletion and cytosolic free calcium. J Clin Invest 1993;92(1):17–24.

    Article  CAS  Google Scholar 

  272. Green RM, Hoda F, Ward KL. Molecular cloning and characterization of the murine bile salt export pump. Gene 2000;241(1):117–123.

    Article  CAS  Google Scholar 

  273. Funk C, Ponelle C, Scheuermann G, Pantze M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol 2001;59(3):627–635.

    CAS  Google Scholar 

  274. Ho ES, Lin DC, Mendel DB, Cihlar T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol 2000;11(3):383–393.

    CAS  Google Scholar 

  275. Lacy SA, Hitchcock MJ, Lee WA, Tellier P, Cundy KC. Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys. Toxicol Sci 1998;44(2):97–106.

    Article  CAS  Google Scholar 

  276. Mulato AS, Ho ES, Cihlar T. Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther 2000;295(1):10–15.

    CAS  Google Scholar 

  277. Tune BM. Nephrotoxicity of beta-lactam antibiotics: mechanisms and strategies for prevention. Pediatr Nephrol 1997;11(6):768–772.

    Article  CAS  Google Scholar 

  278. Faber KN, Muller M, Jansen PL. Drug transport proteins in the liver. Adv Drug Deliv Rev 2003;55(1):107–124.

    Article  CAS  Google Scholar 

  279. Allen JD, Schinkel AH. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther 2002;1(6):427–434.

    CAS  Google Scholar 

  280. Schwarz UI, Gramatte T, Krappweis J, Berndt A, Oertel R, von Richter O, et al. Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans. Clin Pharmacol Ther 1999;65(3):283–290.

    Article  CAS  Google Scholar 

  281. Milne RW, Larsen LA, Jorgensen KL, Bastlund J, Stretch GR, Evans AM. Hepatic disposition of fexofenadine: influence of the transport inhibitors erythromycin and dibromosulphothalein. Pharm Res 2000;17(12):1511–1515.

    Article  CAS  Google Scholar 

  282. Hamman MA, Bruce MA, Haehner-Daniels BD, Hall SD. The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 2001;69(3):114–121.

    Article  CAS  Google Scholar 

  283. Pauli-Magnus C, von Richter O, Burk O, Ziegler A, Mettang T, Eichelbaum M, et al. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther 2000;293(2):376–382.

    CAS  Google Scholar 

  284. Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S, et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002;62(17):4955–4962.

    CAS  Google Scholar 

  285. Jamroziak K, Mlynarski W, Balcerczak E, Mistygacz M, Trelinska J, Mirowski M, et al. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol 2004;72(5):314–321.

    Article  CAS  Google Scholar 

  286. Yates CR, Zhang W, Song P, Li S, Gaber AO, Kotb M, et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol 2003;43(6):555–564.

    CAS  Google Scholar 

  287. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am J Cardiol 2004;93(8):1046–1050.

    Article  CAS  Google Scholar 

  288. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001;70(2):189–199.

    Article  CAS  Google Scholar 

  289. Hebert MF, Dowling AL, Gierwatowski C, Lin YS, Edwards KL, Davis CL, et al. Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics 2003;13(11):661–674.

    Article  CAS  Google Scholar 

  290. Brant SR, Panhuysen CI, Nicolae D, Reddy DM, Bonen DK, Karaliukas R, et al. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet 2003;73(6):1282–1292.

    Article  CAS  Google Scholar 

  291. Singaraja RR, Brunham LR, Visscher H, Kastelein JJ, Hayden MR. Efflux and Atherosclerosis: the Clinical and Biochemical Impact of Variations in the ABCA1 Gene. Arterioscler Thromb Vasc Biol 2003;23(8):1322–1332.

    Article  CAS  Google Scholar 

  292. Frikke-Schmidt R, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J Clin Invest 2004;114(9):1343–1353.

    CAS  Google Scholar 

  293. Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 2004;305(5685):869–872.

    Article  CAS  Google Scholar 

  294. Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T, et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002;1(8):611–616.

    CAS  Google Scholar 

  295. Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, Principe P, et al. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther 2004;76(1):38–44.

    Article  CAS  Google Scholar 

  296. Shu Y, Leabman MK, Feng B, Mangravite LM, Huang CC, Stryke D, et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci USA 2003;100(10):5902–5907.

    Article  CAS  Google Scholar 

  297. Kerb R, Brinkmann U, Chatskaia N, Gorbunov D, Gorboulev V, Mornhinweg E, et al. Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics 2002;12(8):591–595.

    Article  CAS  Google Scholar 

  298. Leabman MK, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, et al. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 2002;12(5):395–405.

    Article  CAS  Google Scholar 

  299. Letschert K, Keppler D, Konig J. Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics 2004;14(7):441–452.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Pediatrics and Pharmacology, Vanderbilt University School of Medicine, Nashvillle, TN, USA

    Richard H. Ho MD

  2. Division of Clinical Pharmacology, Department of Medicine, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada

    Richard B. Kim MD

Authors
  1. Richard H. Ho MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard B. Kim MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. School of Nursing, University of Pennsylvania, Guardian Dr. 420, Philadelphia, 19104, U.S.A.

    Joseph I. Boullata

  2. Dept. Surgery, Temple University Hospital, N. Broad St. 3401, Philadelphia, 19140, U.S.A.

    Vincent T. Armenti

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Ho, R.H., Kim, R.B. (2009). Drug Transporters. In: Boullata, J., Armenti, V. (eds) Handbook of Drug-Nutrient Interactions. Nutrition and Health. Humana Press. https://doi.org/10.1007/978-1-60327-362-6_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-362-6_3

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60327-363-3

  • Online ISBN: 978-1-60327-362-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation